The shares of Amarin Corp. plc, which has research-and-development headquarters in Groton, fell sharply Tuesday after the company disclosed that regulators have not yet decided whether to grant the maximum five-year protection from generic competition for its heart drug Vascepa.
Drugs like Vascepa that are designated as new chemical entities usually enjoy a five-year period of protection, so the lack of quick action by the U.S. Food and Drug Administration led to speculation that regulators might opt for three-year exclusivity.
The stock finished the day down about 6 percent, and analysts predicted more volatility until the FDA ruling is made public.
Have you ever spotted any celebrities around the region? Tell us who, where and when via email to tips@theday.com. Include photos if possible.
Harvard has received some unwelcome attention recently over a cheating scandal potentially involving at least 125 students. How common do you think cheating is on American campuses?
|
||||||||||||||||
HIDE COMMENTS
HIDE COMMENTS